This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Since the first implementation in 2002 by Alain Cribier, transcatheter aorticvalve replacement (TAVR) has become a standard procedure for high-risk and elderly patients with severe aorticvalvestenosis. Recently, the use of TAVR has expanded to relatively younger patients with low to moderate surgical risk.
Objectives Lipoprotein(a) (Lp(a)) is associated with an increased incidence of native aorticstenosis, which shares similar pathological mechanisms with bioprosthetic aorticvalve (bAV) degeneration. However, evidence regarding the role of Lp(a) concentrations in bAV degeneration is lacking.
No doubt ,the Aortic interventional world is applauding and everyone is joining the party. Because it was done in 2010-2013. As a cardiologist, very soon we will be allowed legally to choose TAVI even in more younger , low risk cohort of Aorticstenosis without co-morbid conditions. Now, some academic queries ?
Transcatheter aorticvalve replacement (TAVR) has emerged as the preferred treatment for older patients suffering from severe aorticvalvestenosis, surpassing the annual patient count of those opting for surgical aorticvalve replacement. in 2007-2010 to 5.5% in 2019-2022. 1.72; P = 0.002).
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content